Cargando…
A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2.
In a pilot study six patients received 4 days' treatment with interleukin 2 (IL-2) [cumulative dose (CD) 264 +/- 26 x 10(6) IU m-2] and C1 esterase inhibitor (C1-INH) (loading dose 2,000 U, followed by 500-1,000 U twice daily). Toxicity was compared with that in patients given 4 days' trea...
Autores principales: | Ogilvie, A. C., Baars, J. W., Eerenberg, A. J., Hack, C. E., Pinedo, H. M., Thijs, L. G., Wagstaff, J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1994
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968861/ https://www.ncbi.nlm.nih.gov/pubmed/8123494 |
Ejemplares similares
-
The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.
por: Baars, J. W., et al.
Publicado: (1992) -
Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), and its exacerbation during intravenous therapy with IL-2.
por: Baars, J. W., et al.
Publicado: (1992) -
No prominent role for complement C1-esterase inhibitor in Marfan syndrome mice
por: Hibender, Stijntje, et al.
Publicado: (2022) -
Recombinant human C1 esterase inhibitor as prophylactic treatment in idiopathic non‐histaminergic angioedema
por: Alizadeh Aghdam, Mehran, et al.
Publicado: (2022) -
The perioperative course of C1-esterase-inhibitor: evidence for an early deficiency
por: Cobas Meyer, M, et al.
Publicado: (1999)